Specialty Generics Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Specialty Generics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Injectable, Oral, others), By Indication (Oncology, Autoimmune Diseases, Infectious Diseases, others), By Distribution Channel (Retail Pharmacies, Specialty Pharmacies, Hospital Pharmacies), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Specialty Generics Market is set for substantial growth, projected to increase from USD 56.69 Billion in 2025 to USD 99.12 Billion by 2031 at a 9.76% CAGR. This sector focuses on bioequivalent versions of highly complex pharmaceutical products, such as injectables and biologics, used to treat chronic or rare conditions like cancer and autoimmune disorders, often requiring specialized handling. The market's expansion is fundamentally driven by the escalating prevalence of chronic diseases and the critical imperative for healthcare cost containment, particularly following the patent expiration of major originator drugs. The economic value of affordable alternatives is significant, with generic and biosimilar medicines saving the U.S. healthcare system $467 billion in 2024.
Market Driver
A major catalyst for the Global Specialty Generics Market is the impending patent cliff, with approximately $236 billion worth of pharmaceutical products facing generic and biosimilar competition between 2025 and 2030, creating immense opportunities for generic manufacturers to introduce bioequivalent alternatives and alleviate the financial burden of expensive originator therapies. The global increase in complex chronic and rare diseases further amplifies demand, with 76.4% of U.S. adults reporting one or more chronic conditions in 2023, driving manufacturers like Sandoz to expand global operations, having delivered over 902 million patient treatments across more than 100 countries.
Market Challenge
Despite this robust growth potential, the Global Specialty Generics Market faces considerable challenges, primarily stemming from a rigorous regulatory landscape. Unlike standard oral formulations, the development of bioequivalent injectables and biologics requires intricate manufacturing processes and extensive clinical trials, imposing significant financial and technical burdens. These elevated standards limit the number of capable manufacturers, creating a bottleneck that delays the availability of cost-effective treatments and restricts market expansion. A telling statistic reveals that while 118 biologics are expected to lose patent exclusivity over the next decade, only 12 of these molecules had biosimilars in development in 2025, highlighting how regulatory complexity and high development costs deter the initiation of new programs.
Market Trends
In response to these market dynamics, a key trend sees market players increasingly forming strategic alliances and engaging in mergers to share risks, leverage expertise in regulatory affairs and global distribution, and navigate the substantial capital and technical complexities of commercializing biosimilars and specialty injectables. This consolidation accelerates market entry and expands commercial reach, as exemplified by Biocon Biologics exceeding $1 billion in annual revenue post-integration of Viatris' biosimilars business. Concurrently, manufacturers are strategically expanding their portfolios into complex generics like biosimilars, peptides, and long-acting injectables to counter pricing pressures on oral solid dosages and secure more sustainable revenue streams with less competitive intensity, a shift evidenced by Sandoz's global biosimilar pipeline growing to 28 molecules.
Key Market Players
* Teva Pharmaceuticals Industries Ltd
* Viatris Inc.
* Novartis AG
* Hikma Pharmaceuticals PLC
* Bausch Health Companies Inc.
* Dr. Reddy's Laboratories Ltd.
* Endo Pharmaceuticals Inc.
* Apotex Corporation
* Sun Pharmaceutical Industries Ltd
* STADA Arzneimittel AG
Report Scope
In this report, the Global Specialty Generics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Specialty Generics Market, By Route of Administration
* Injectable
* Oral
* others
# Specialty Generics Market, By Indication
* Oncology
* Autoimmune Diseases
* Infectious Diseases
* others
# Specialty Generics Market, By Distribution Channel
* Retail Pharmacies
* Specialty Pharmacies
* Hospital Pharmacies
# Specialty Generics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Specialty Generics Market.
Available Customizations:
Global Specialty Generics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Specialty Generics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Injectable, Oral, others)
5.2.2. By Indication (Oncology, Autoimmune Diseases, Infectious Diseases, others)
5.2.3. By Distribution Channel (Retail Pharmacies, Specialty Pharmacies, Hospital Pharmacies)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Specialty Generics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration
6.2.2. By Indication
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Specialty Generics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Indication
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Specialty Generics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Indication
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Specialty Generics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Indication
6.3.3.2.3. By Distribution Channel
7. Europe Specialty Generics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration
7.2.2. By Indication
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Specialty Generics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Indication
7.3.1.2.3. By Distribution Channel
7.3.2. France Specialty Generics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Indication
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Specialty Generics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Indication
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Specialty Generics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Route of Administration
7.3.4.2.2. By Indication
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Specialty Generics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Indication
7.3.5.2.3. By Distribution Channel
8. Asia Pacific Specialty Generics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration
8.2.2. By Indication
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Specialty Generics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Indication
8.3.1.2.3. By Distribution Channel
8.3.2. India Specialty Generics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Indication
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Specialty Generics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Indication
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Specialty Generics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Route of Administration
8.3.4.2.2. By Indication
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Specialty Generics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Route of Administration
8.3.5.2.2. By Indication
8.3.5.2.3. By Distribution Channel
9. Middle East & Africa Specialty Generics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration
9.2.2. By Indication
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Specialty Generics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Indication
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Specialty Generics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Indication
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Specialty Generics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Indication
9.3.3.2.3. By Distribution Channel
10. South America Specialty Generics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration
10.2.2. By Indication
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Specialty Generics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Route of Administration
10.3.1.2.2. By Indication
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Specialty Generics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Route of Administration
10.3.2.2.2. By Indication
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Specialty Generics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Route of Administration
10.3.3.2.2. By Indication
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Specialty Generics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Teva Pharmaceuticals Industries Ltd
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Viatris Inc.
15.3. Novartis AG
15.4. Hikma Pharmaceuticals PLC
15.5. Bausch Health Companies Inc.
15.6. Dr. Reddy's Laboratories Ltd.
15.7. Endo Pharmaceuticals Inc.
15.8. Apotex Corporation
15.9. Sun Pharmaceutical Industries Ltd
15.10. STADA Arzneimittel AG
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們